77236-35-2

Usage

InChI:InChI=1/C44H54N8O7/c1-28(54)39(51-40(55)34(46)18-10-11-21-45)43(58)50-37(24-30-15-6-3-7-16-30)44(59)52-22-12-20-38(52)42(57)49-36(23-29-13-4-2-5-14-29)41(56)48-32(27-53)25-31-26-47-35-19-9-8-17-33(31)35/h2-9,12-17,19-20,26-28,32,34,36-39,47,54H,10-11,18,21-25,45-46H2,1H3,(H,48,56)(H,49,57)(H,50,58)(H,51,55)/t28-,32-,34+,36+,37+,38+,39+/m1/s1

Upstream product

• 87282-39-1 cyclo-(L-phenylalanyl-D-tryptophanyl-Nε-benzyloxycarbonyl-L-lysyl-L-threonyl-L-phenylalanyl-L-proline) 

Relevant academic research and scientific papers

Cyclic peptide synthesis with thioacids

(Figure Presented) C-Terminal amino acid 9-fluorenylmethylthioesters may be carried through Boc chemistry solution phase peptide synthesis sequences. After insertion of the final residue in the form of an Fmoc carbamate, treatment with piperidine releases a seco-peptide as a C-terminal thioacid that on treatment with Sanger's reagent undergoes cyclization to a cyclic peptide. Cyclic penta- and hexapeptides have been synthesized in this manner, as has a cyclic glycopeptide. Functional group compatibility with alcohols and carboxylic acids is demonstrated.

Cyclic and bridged cyclic somatostatin analogs useful as analgesic agents

Cyclic and bridged cyclic somatostatin analogs have been found to be effective in the treatment of peripherally mediated pain and are therefore useful as analgesic agents.

Cyclic and bridged cyclic somatostatin analogs useful as local anti-inflammatory agents

Cyclic and bridged cyclic somatostatin analogs have been found to be useful as local anti-inflammatory agents in the treatment of such conditions, as, for example, psoriasis, eczema, seborrhea, and other localized inflammatory and allergic conditions.

Cyclic hexapeptide somatostatin analogs

Somatostatin analogs are prepared wherein a cyclic hexapeptide contains a secondary amino acid which replaces seven of the ring amino acids of somatostatin. The cyclic hexapeptides are easier to synethesize, have a longer duration of activity, and many have a greater level of activity than somatostatin. The compounds have the properties of inhibiting the release of glucagon, growth hormone and insulin. Certain of the compounds also are capable of inhibiting the release of gastric acid secretions. The compounds are particularly useful in the treatment of acromegaly, diabetes, diabetic retinopathy and peptic ulcers. These cyclic hexapeptides are prepared by the solid phase method.